home / stock / acst:cc / acst:cc quote
Last: | $1.34 |
---|---|
Change Percent: | -2.19% |
Open: | $1.34 |
Close: | $1.34 |
High: | $1.34 |
Low: | $1.3 |
Volume: | 6,685 |
Last Trade Date Time: | 05/06/2022 04:55:07 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.34 | $1.34 | $1.34 | $1.34 | $1.3 | 6,685 | 05-06-2022 |
$1.37 | $1.34 | $1.37 | $1.37 | $1.34 | 2,038 | 05-05-2022 |
$1.35 | $1.35 | $1.35 | $1.38 | $1.35 | 1,290 | 05-04-2022 |
$1.34 | $1.35 | $1.34 | $1.39 | $1.34 | 4,028 | 05-03-2022 |
$1.33 | $1.32 | $1.33 | $1.36 | $1.32 | 4,675 | 05-02-2022 |
$1.32 | $1.36 | $1.32 | $1.37 | $1.32 | 5,425 | 04-29-2022 |
$1.33 | $1.36 | $1.33 | $1.37 | $1.33 | 2,433 | 04-28-2022 |
$1.34 | $1.36 | $1.34 | $1.38 | $1.32 | 7,764 | 04-27-2022 |
$1.37 | $1.39 | $1.37 | $1.39 | $1.36 | 5,140 | 04-26-2022 |
$1.39 | $1.37 | $1.39 | $1.39 | $1.36 | 4,504 | 04-25-2022 |
$1.41 | $1.41 | $1.41 | $1.41 | $1.36 | 7,273 | 04-22-2022 |
$1.45 | $1.51 | $1.45 | $1.51 | $1.42 | 12,248 | 04-21-2022 |
$1.46 | $1.46 | $1.46 | $1.51 | $1.44 | 13,219 | 04-20-2022 |
$1.48 | $1.47 | $1.48 | $1.48 | $1.45 | 9,032 | 04-19-2022 |
$1.48 | $1.5 | $1.48 | $1.5 | $1.45 | 5,378 | 04-18-2022 |
$1.52 | $1.53 | $1.52 | $1.6 | $1.51 | 14,437 | 04-15-2022 |
$1.52 | $1.53 | $1.52 | $1.6 | $1.51 | 14,234 | 04-14-2022 |
$1.53 | $1.45 | $1.53 | $1.55 | $1.45 | 5,819 | 04-13-2022 |
$1.43 | $1.47 | $1.43 | $1.47 | $1.43 | 2,711 | 04-12-2022 |
$1.44 | $1.44 | $1.44 | $1.44 | $1.4 | 6,174 | 04-11-2022 |
News, Short Squeeze, Breakout and More Instantly...
Acasti Pharma Inc. Company Name:
ACST:CC Stock Symbol:
TSXVC Market:
Projected Cash Runway Extends into Second Calendar Quarter 2026, Well Beyond Potential 1H 2025 Submission of GTX-104 New Drug Application (NDA) Patient Enrollment in Pivotal STRIVE-ON Phase 3 Trial Continues, On Track for NDA Submission Timeline Poster Highlighting the STRIVE-ON...
PRINCETON, N.J., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine that addresses the high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (...
PRINCETON, N.J., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel intravenous formulation of nimodipine being developed to address the high unmet medical needs for a rare disease, aneurysmal S...